查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1595054

組織工程皮膚替代品的全球市場

Tissue Engineered Skin Substitutes
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 89 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球組織工程皮膚替代品市場將達到 54 億美元

組織工程皮膚替代品的全球市場預計 2023 年為 31 億美元，預計到 2030 年將達到 54 億美元，2023-2030 年分析期間複合年成長率為 8.2%。生物替代品是本報告分析的細分市場之一，預計複合年成長率為 8.8%，到分析期結束時將達到 29 億美元。分析期間，合成替代品領域的複合年成長率預計為 8.0%。

美國市場預估8.53億美元，中國預期複合年成長率7.6%

到 2023 年，美國組織工程皮膚替代品市場預計將達到 8.53 億美元。中國作為全球第二大經濟體，預計2030年市場規模將達8.225億美元，2023年至2030年複合年成長率為7.6%。其他值得注意的區域市場包括日本和加拿大，在分析期間預計複合年成長率分別為 7.6% 和 6.6%。在歐洲，德國的複合年成長率預計約為 6.5%。

全球組織工程皮膚替代品市場 - 主要趨勢和促進因素總結

組織工程皮膚替代品如何徹底改變創傷護理？

組織工程皮膚替代品是先進的生物材料，旨在取代遭受嚴重燒燙傷、慢性傷口和其他皮膚損傷的患者受損或流失的皮膚組織。這些替代品是使用生物相容性支架、細胞和生長因子開發的，以模仿天然皮膚的結構和功能，促進更快的癒合並減少疤痕。組織工程皮膚替代品可作為同種異體移植物、自體移植物和異質骨移植，為重組手術、皮膚科和傷口處理提供重要的解決方案。隨著醫療保健系統專注於改善患者的治療效果和加快康復速度，組織工程皮膚替代品作為傳統皮膚移植的有效替代品正在取得進展。

組織工程皮膚替代品市場的關鍵部分是什麼？

主要產品類型包括細胞替代品、細胞替代品、複合替代品。細胞替代品主要由膠原蛋白等生物材料製成，廣泛應用於燒傷治療和慢性傷口管理，佔有很大佔有率。含有活細胞的細胞替代品由於能夠與患者皮膚融合併促進癒合而越來越受歡迎。組織工程皮膚替代品的應用包括燒傷管理、糖尿病潰瘍、壓瘡和重組手術，其中燒傷管理佔最大部分，因為嚴重情況下皮膚修復至關重要。組織工程皮膚替代品的最終使用者包括醫院、傷口護理中心和專科診所。醫院在市場中處於領先地位，將這些替代品用於燒傷治療、重組手術、慢性傷口管理以及其他需要快速癒合和縮短住院時間的情況。傷口護理中心使用皮膚替代來治療糖尿病潰瘍、褥瘡和其他不癒合傷口，以改善患者康復並降低感染風險。此外，專業診所在整容和重組手術中使用這些替代品，以實現更好的美容效果和更短的恢復時間。

組織工程皮膚替代品如何應用於醫療保健？

在醫院，組織工程皮膚替代品用於治療嚴重燒燙傷、深度傷口和手術後恢復，以促進更快的癒合並最大限度地減少疤痕形成。在傷口護理中心，這些替代品在糖尿病潰瘍和褥瘡等慢性傷口的治療中發揮著重要作用，有助於皮膚組織再生和預防感染疾病。在重組和整容手術中，皮膚替代品可以恢復美觀並改善皮膚功能，特別是在創傷、先天性缺陷和癌症手術的情況下。此外，在這些皮膚替代中使用先進的生物材料可以減少對捐贈者皮膚移植的需求，從而最大限度地減少併發症和恢復時間。

推動組織工程皮膚替代品市場成長的因素有哪些？

組織工程皮膚替代品市場的成長受到多種因素的推動，包括燒傷和慢性傷口盛行率的上升、組織工程的進步以及對更好的創傷護理解決方案的需求不斷增加。生物工程支架、注入生長因子的替代品以及改進與自然組織的整合等創新正在擴大整個醫療保健領域的應用。組織工程皮膚替代品專注於改善患者的治療效果、縮短復原時間並最大限度地減少住院時間，為傷口管理提供了重要的好處，進一步推動了需求。此外，醫療保健支出的增加、對先進傷口護理的認知不斷提高以及對再生醫學的投資不斷增加，都有助於市場成長並推動組織工程皮膚替代品在各種醫療環境中的採用。

部分

產品（生物、合成、生物合成）；最終用途（急性、慢性）；最終使用者（醫院、傷口護理中心、其他最終使用者）

受訪企業範例（33家知名企業）

  • Amarantus Bioscience Holdings, Inc.
  • BSN medical
  • ConvaTec Group PLC
  • Integra LifeSciences Corporation
  • Kerecis
  • LifeNet Health
  • Mallinckrodt
  • Medline Industries, Inc.
  • MiMedx
  • Molnlycke Health Care AB
  • Organogenesis Inc.
  • Regenicin
  • Smith & Nephew
  • Tissue Regenix

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他領域

第4章 比賽

簡介目錄
Product Code: MCP22954

Global Tissue Engineered Skin Substitutes Market to Reach US$5.4 Billion by 2030

The global market for Tissue Engineered Skin Substitutes estimated at US$3.1 Billion in the year 2023, is expected to reach US$5.4 Billion by 2030, growing at a CAGR of 8.2% over the analysis period 2023-2030. Biological Substitutes, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Synthetic Substitutes segment is estimated at 8.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$853.0 Million While China is Forecast to Grow at 7.6% CAGR

The Tissue Engineered Skin Substitutes market in the U.S. is estimated at US$853.0 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$822.5 Million by the year 2030 trailing a CAGR of 7.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.6% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.

Global Tissue Engineered Skin Substitutes Market - Key Trends and Drivers Summarized

How Are Tissue Engineered Skin Substitutes Revolutionizing Wound Care?

Tissue engineered skin substitutes are advanced biomaterials designed to replace damaged or lost skin tissues in patients suffering from severe burns, chronic wounds, and other skin injuries. These substitutes are developed using biocompatible scaffolds, cells, and growth factors to mimic the structure and function of natural skin, promoting faster healing and reducing scarring. Available as allogeneic, autologous, and xenogeneic grafts, tissue engineered skin substitutes provide vital solutions in reconstructive surgery, dermatology, and wound management. As healthcare systems emphasize better patient outcomes and faster recovery, tissue engineered skin substitutes have gained traction as effective alternatives to traditional skin grafts.

What Are the Key Segments in the Tissue Engineered Skin Substitutes Market?

Major product types include acellular, cellular, and composite substitutes. Acellular substitutes, made primarily from collagen or other biomaterials, hold a significant share due to their wide use in burn treatments and chronic wound management. Cellular substitutes, which contain living cells, are gaining popularity for their ability to integrate with the patient’s skin and enhance healing. Applications of tissue engineered skin substitutes cover burn management, diabetic ulcers, pressure ulcers, and reconstructive surgeries, with burn management representing the largest segment due to the critical need for rapid skin regeneration in severe cases. End-users of tissue engineered skin substitutes include hospitals, wound care centers, and specialty clinics. Hospitals lead the market, utilizing these substitutes for burn treatments, reconstructive surgeries, and chronic wound management, where rapid healing and reduced hospitalization are critical. Wound care centers use skin substitutes for treating diabetic ulcers, pressure sores, and other non-healing wounds, improving patient recovery and reducing the risk of infection. Additionally, specialty clinics employ these substitutes in cosmetic and reconstructive surgeries, ensuring better aesthetic outcomes and faster recovery times.

How Are Tissue Engineered Skin Substitutes Applied in Healthcare?

In hospitals, tissue engineered skin substitutes are used to treat severe burns, deep wounds, and post-surgical recovery, promoting faster healing and minimizing scar formation. In wound care centers, these substitutes play a critical role in managing chronic wounds like diabetic ulcers and pressure sores, where they help regenerate skin tissues and prevent infections. In reconstructive and cosmetic surgeries, skin substitutes provide aesthetic restoration and improved skin function, particularly in cases of trauma, congenital defects, and post-cancer surgeries. The use of advanced biomaterials in these substitutes also reduces the need for donor skin grafts, minimizing complications and recovery times.

What Factors Are Driving the Growth in the Tissue Engineered Skin Substitutes Market?

The growth in the Tissue Engineered Skin Substitutes market is driven by several factors, including rising incidence of burns and chronic wounds, advancements in tissue engineering, and increasing demand for better wound care solutions. Innovations like bioengineered scaffolds, growth factor-infused substitutes, and improved integration with natural tissues have expanded their applications across healthcare. The focus on improving patient outcomes, reducing recovery times, and minimizing hospital stays has further fueled demand, as tissue engineered skin substitutes offer critical benefits in wound management. Additionally, growing healthcare spending, rising awareness of advanced wound care treatments, and increased investment in regenerative medicine have contributed to market growth, encouraging the adoption of tissue engineered skin substitutes in diverse medical settings.

SCOPE OF STUDY:

The report analyzes the Tissue Engineered Skin Substitutes market in terms of US$ Thousand by the following Application; End-Use; Product, and Geographic Regions/Countries:

Segments:

Product (Biological, Synthetic, Biosynthetic); Application (Acute, Chronic); End-Use (Hospitals, Wound Care Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 33 Featured) -

  • Amarantus Bioscience Holdings, Inc.
  • BSN medical
  • ConvaTec Group PLC
  • Integra LifeSciences Corporation
  • Kerecis
  • LifeNet Health
  • Mallinckrodt
  • Medline Industries, Inc.
  • MiMedx
  • Molnlycke Health Care AB
  • Organogenesis Inc.
  • Regenicin
  • Smith & Nephew
  • Tissue Regenix

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Tissue Engineered Skin Substitutes - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Use in Burn Treatment and Wound Care Spurs Market Demand
    • Advancements in Bio-Engineered Skin Solutions Drive Market Growth
    • Increasing Adoption in Diabetic Foot Ulcer Management Expands Addressable Market
    • Rising Focus on Chronic Wound Care Strengthens Business Case
    • Focus on Reducing Surgical Recovery Time Enhances Demand
    • Increasing Use of Collagen-Based and Synthetic Skin Substitutes Expands Market Opportunities
    • Advancements in 3D Bioprinting Technologies Propel Tissue Engineering Solutions
    • Growing Emphasis on Minimally Invasive Procedures Drives Adoption
    • Rising Use of Skin Substitutes in Reconstructive Surgeries Sustains Market Growth
    • Focus on Cosmetic and Aesthetic Applications Expands Market Scope
    • Increasing Focus on Developing Off-the-Shelf Skin Substitutes Generates Opportunities
    • Growing Use in Pediatric Wound Care Propels Market Expansion
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Tissue Engineered Skin Substitutes Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World 7-Year Perspective for Tissue Engineered Skin Substitutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Biological by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World 7-Year Perspective for Biological by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Synthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 7: World 7-Year Perspective for Synthetic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Biosynthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World 7-Year Perspective for Biosynthetic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Acute by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World 7-Year Perspective for Acute by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Chronic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 13: World 7-Year Perspective for Chronic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Wound Care Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Wound Care Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 19: World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 22: USA Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 23: USA 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 25: USA 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Canada 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: Canada 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • JAPAN
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 34: Japan Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Japan 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 37: Japan 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • CHINA
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 40: China Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 41: China 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 42: China Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 43: China 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • EUROPE
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 46: Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • FRANCE
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 52: France Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 53: France 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 54: France Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 55: France 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • GERMANY
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 58: Germany Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 59: Germany 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 60: Germany Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 61: Germany 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • ITALY
    • TABLE 64: Italy Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Italy 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 66: Italy Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Italy 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • UNITED KINGDOM
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 70: UK Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 71: UK 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 72: UK Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 73: UK 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 76: Rest of Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 77: Rest of Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 82: Asia-Pacific Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 83: Asia-Pacific 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 88: Rest of World Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 89: Rest of World 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 91: Rest of World 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of World 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030

IV. COMPETITION